Mereo BioPharma Group plc · NASDAQ:MREO
Mereo BioPharma — H1 2019 Earnings Presentation
10 slides from Mereo BioPharma's earnings presentation, Sep 17, 2019
Slide 1: 2019 Interims Corporate Update Conference Call
2019 INTERIMS CORPORATE UPDATE CONFERENCE CALL SEPTEMBER 17, 2019
Slide 2: Disclaimer
DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. This presentation has been prepared by Mereo BioPharma Group plc
Slide 3: Core Strategy Focused on Rare Diseases
CORE STRATEGY FOCUSED ON RARE DISEASES… Setrusumab Avelestat Osteogenesis Imperfecta (OI) Alpha-1 Antitrypsin Deficiency (AATD) • Positive Phase 2b open label 6-month data reported in • Phase 2 proof-of-concept study currently enrolling May 2019; 12-month randomized data expected Q4 2019 patients wi
Slide 4: Setrusumab for Osteogenesis Imperfecta (OI)
SETRUSUMAB FOR OSTEOGENESIS IMPERFECTA (OI) • OI is rare genetic bone disease characterized by frequent bone fractures, brittle teeth, and other physical symptoms • There are currently no FDA or EMA approved therapies for OI • Setrusumab is a human monoclonal antibody targeting sclerostin that has b
Slide 5: Phase 2b ASTEROID Study: Topline 12-Month Data Expected Q4 2019
PHASE 2B ASTEROID STUDY: TOPLINE 12-MONTH DATA EXPECTED Q4 2019 ASTEROID Study Design Encouraging 6-Month Data Fully Enrolled Trial arms: Tr vBMD as measured by HRpQCT Positive 6-month Change from baseline Absolute (%) Mean (%) 112 Three open label data different reported in May 3 Months (n=12) 1.32
Slide 6: Setrusumab Pediatric Phase 3 Pivotal Study Ready to Begin
SETRUSUMAB PEDIATRIC PHASE 3 PIVOTAL STUDY READY TO BEGIN Planned 24 patients 5-18 years Pivotal study enrollment: One month dose approved in EU Total study duration ~165 finding – 3 doses versus placebo and Canada Severe OI Patients Types I, III and IV Additional 128 patients Randomized 1:1 placebo
Slide 7: Alvelestat for Alpha-1 Antitrypsin Deficiency (AATD)
ALVELESTAT FOR ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) Scientific Rationale Phase 2 Proof of Concept Study • AATD is a rare, serious genetic disorder that Enrolling Trial arms: results in early onset pulmonary disease ~165 Two different dosing arms Topline data vs. expected • AATD patients either lack
Slide 8: Strong Operational Progress Sets the Stage for 2H19/2020
STRONG OPERATIONAL PROGRESS SETS THE STAGE FOR AN EXCITING 2H19/2020 RARE DISEASES NON-RARE DISEASES CORPORATE SETRUSUMAB ALVELESTAT LEFLUTROZOLE • Merger with OncoMed completed April 2019 added • Six month extension study • two new oncology product Adult Phase 2b completed • Phase 2 POC study (12 m
Slide 9: 1H 2019 Financial Highlights
1H 2019 FINANCIAL HIGHLIGHTS (£ in millions) 1H 2019 1H 2018 Research & Development 11.9 10.9 Operating Expenses 6.5 7.1 (£ in millions) 1H 2019 1H 2018 Cash & cash deposits & 36.1 36.9 short-term investments Total shares outstanding as at June 30, 2019 97,959,622 ADR’s (each representing 5 underlyi
Slide 10: Thank You
—_ TA Mereo BioPharma ~~
Mereo BioPharma Group — H1 2019 Earnings Presentation on 6ix